Form 4: Phathom Pharmaceuticals Officer Sells Shares for Tax

Phathom Pharmaceuticals' Principal Accounting Officer, Robert Charles Breedlove, disposed of 776 shares of common stock to cover tax withholding obligations.

Summary

• Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., disposed of 776 shares of common stock.
• The transaction occurred on January 21, 2026, at a price of $13.61 per share.
• This disposition was to satisfy tax withholding obligations related to restricted stock units.
• Following the transaction, Mr. Breedlove directly owns 47,068 shares and indirectly owns 6,945.4 shares through a 401(k).

Sentiment

Score: 5

Explanation: The transaction is a routine tax withholding event and is neutral in sentiment, reflecting neither positive nor negative operational or financial performance.

Future Outlook

NA

Industry Context

This is a routine insider transaction common across all industries when restricted stock units vest, and shares are withheld to cover tax obligations. It does not reflect any specific industry trend or competitive action.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an officer to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and generally do not indicate a change in the company's fundamentals or the officer's long-term view of the company. Therefore, it provides no new information to warrant a change in investment recommendation, suggesting a 'hold' position is appropriate based solely on this filing.

Keywords

Phathom Pharmaceuticals, PHAT, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Robert Charles Breedlove, Principal Accounting Officer